Today, we shared our Q1 2025 financial results. View our recent corporate highlights and upcoming milestones in the press release: investors.mbxbio.com/news-releases/…

Next month, our CEO & Co-Founder, Kent Hawryluk, will present at and participate in 1x1 meetings at the Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference. Learn more and access the live webcasts in the full release: investors.mbxbio.com/news-releases/…

We are proud to celebrate 50 years of toxicology excellence with Michael A. Dorato, Ph.D., DABT, Fellow ATS, FRSB, our SVP, Discovery & Non-Clinical Development! Join us in congratulating Mike for earning his DABT recertification through 2030. #MBXSpotlight #MBXellence

Rooted in science, we’re driving innovation for better health outcomes for patients. At MBX, we’re advancing our novel PTH replacement investigational therapy to address unmet needs in #hypoparathyroidism. American Thyroid Association #WorldThyroidDay

At MBX Biosciences, our core values are the pillars of our organization. We’re guided by transparency, integrity, teamwork & innovation as we work to make a meaningful impact on patients’ lives. Learn more: mbxbio.com/about-us/#core…

At MBX, we’re committed to addressing the unmet needs of people with #hypoparathyroidism, a rare #endocrine disorder that affects many aspects of patients’ daily lives. Follow along for more as we recognize Hypoparathyroidism Awareness Day and those impacted by this condition.

MBX stands with the #hypoparathyroidism community, especially on World Hypoparathyroidism Awareness Day, where we honor those living with this rare and complex condition. We remain committed to advancing new treatment options to bring meaningful change to patients’ lives.

This afternoon, our CEO & Co-Founder, Kent Hawryluk, will discuss the IPO process & what companies can expect after going public on a panel at the Global Entrepreneurship Congress Indiana 2025. Learn more about the session & event: genglobal.org/gec/unlocking-… Global Entrepreneurship Network

#ICYMI, CEO & Co-Founder, Kent Hawryluk, and our CMO, Sam Azoulay, M.D., participated in a fireside chat during the Jefferies Global Healthcare Conference. Learn more: investors.mbxbio.com/news-releases/… #JefferiesHealthcare

Today, our CEO & Co-Founder, Kent Hawryluk, will present and participate in 1x1 meetings at the Goldman Sachs Global Healthcare Conference. Learn more and access the webcast in the full release: investors.mbxbio.com/news-releases/…

Today, we announced our attendance and upcoming poster presentations at the 85th American Diabetes Association Scientific Sessions. Full presentation details can be found here: investors.mbxbio.com/news-releases/… American Diabetes Association - DiabetesPro

#News: We submitted our IND for our long-acting GLP-1/GIP receptor co-agonist prodrug for #obesity. Designed for once-monthly dosing & improved GI tolerability, we hope it will provide better adherence and weight loss. Read more in the PR: investors.mbxbio.com/news-releases/…

Members of our MBX team will be in #Boston for the BIO International Convention this week. Be sure to connect with us while you are there! Biotechnology Innovation Organization #BIO2025

#News: Join us in welcoming Dr. Andreas Moraitis as our new SVP of Clinical Development. Andreas joins at an important time as we advance our investigational #hypoparathyroidism treatment & full pipeline for endocrine & metabolic diseases. Read more: investors.mbxbio.com/news-releases/…

Our CEO & Co-Founder, Kent Hawryluk and CMO, Sam Azoulay, M.D., will participate in a fireside chat this week at the Piper Sandler 3rd Annual Virtual Obesity Symposium with ADA Takeaways. Contact your PSC rep for registration details. Piper Sandler

At MBX, we have a clear mission to help people with #endocrine & #metabolic disorders live fuller & healthier lives. If you’re inspired by purpose-driven work & want to be part of a team that’s advancing therapies with impact, explore our open positions: mbxbio.com/careers

This week, Richard DiMarchi, Ph.D., Indiana University Prof., MBX co-founder & will present on the discovery process for our novel investigational parathyroid hormone replacement therapy at the 2nd Annual Hypoparathyroidism Summit. endocrine.org/-/media/endocr…

We’re proud to share that our Chief Executive Officer & co-founder, Kent Hawryluk, and co-founder, Richard DiMarchi, Ph.D., have been named to the 2025 #Indiana250: a list of the state’s most influential & impactful leaders for the 2nd in a row. indiana250.com

Today, our CEO & Co-Founder, Kent Hawryluk and CMO, Sam Azoulay, M.D., will participate in a fireside chat at the private virtual UBS Biotech Management Live Call Series.

Today, we shared our Q2 2025 financial results. View our corporate highlights and upcoming milestones in the press release: investors.mbxbio.com/news-releases/… #earnings